162 related articles for article (PubMed ID: 37501955)
1. Prediction of disease-free survival of N1/2 non-small cell lung cancer after adjuvant chemotherapy by the biomarker RPMB.
An N; Yang X
Heliyon; 2023 Jul; 9(7):e18266. PubMed ID: 37501955
[TBL] [Abstract][Full Text] [Related]
2. High RPMB predicts poor disease-free survival of male N1 papillary thyroid cancer after adjuvant radioiodine therapy.
An N; Yang X
Heliyon; 2022 Nov; 8(11):e11783. PubMed ID: 36468103
[TBL] [Abstract][Full Text] [Related]
3. Low RPMB indicates better disease-free survival of adjuvant radiotherapy after radical surgery in thymoma.
An N; Cui L; Yang X
Am J Transl Res; 2023; 15(8):5457-5468. PubMed ID: 37692947
[TBL] [Abstract][Full Text] [Related]
4. Promoter Methylation of DNA Repair Genes Predicts Disease-free Survival of Gastric Adenocarcinoma after Adjuvant Radiotherapy.
An N; Yu Z; He XJ; Zhao YY; Yu L; Zhang YC; Lu HJ; Yang X
Mol Ther Oncolytics; 2020 Sep; 18():109-117. PubMed ID: 32671186
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy and Surgical Resection for N1 Positive Non-small Cell Lung Cancer: Better Than Expected Outcomes.
White A; Kucukak S; Lee DN; Mazzola E; Dolan D; Bueno R; Jaklitsch MT; Swanson SJ
Semin Thorac Cardiovasc Surg; 2021; 33(4):1105-1111. PubMed ID: 33600992
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.
Yan S; Shun-Chang J; Li C; Jie L; Ya-Li L; Ling-Xiong W
BMC Cancer; 2010 Nov; 10():621. PubMed ID: 21067592
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study.
Luo F; Zeng KM; Cao JX; Zhou T; Lin SX; Ma WJ; Yang YP; Zhang ZH; Lu FT; Huang Y; Zhao HY; Zhang L
Lipids Health Dis; 2021 Sep; 20(1):109. PubMed ID: 34544437
[TBL] [Abstract][Full Text] [Related]
8. Comparison of prognostic values of primary tumor and nodal
Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
Eur Radiol; 2019 Oct; 29(10):5288-5297. PubMed ID: 30899978
[TBL] [Abstract][Full Text] [Related]
9. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
Shi Y; Chen L; Li J; Lü YL; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
12. Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features.
Pathak R; Goldberg SB; Canavan M; Herrin J; Hoag JR; Salazar MC; Papageorge M; Ermer T; Boffa DJ
JAMA Oncol; 2020 Nov; 6(11):1741-1750. PubMed ID: 32940636
[TBL] [Abstract][Full Text] [Related]
13. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
[TBL] [Abstract][Full Text] [Related]
14. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction.
Vaidya P; Bera K; Gupta A; Wang X; Corredor G; Fu P; Beig N; Prasanna P; Patil PD; Velu PD; Rajiah P; Gilkeson R; Feldman MD; Choi H; Velcheti V; Madabhushi A
Lancet Digit Health; 2020 Mar; 2(3):e116-e128. PubMed ID: 33334576
[TBL] [Abstract][Full Text] [Related]
15. Unfavorable prognosis of patients with stage II non-small cell lung cancer associated with macroscopic nodal metastases.
Yoshino I; Nakanishi R; Osaki T; Takenoyama M; Taga S; Hanagiri T; Yasumoto K
Chest; 1999 Jul; 116(1):144-9. PubMed ID: 10424518
[TBL] [Abstract][Full Text] [Related]
16. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
17. Mediastinal radiotherapy after adjuvant chemotherapy for resected non-small cell lung cancer with N2 lymphadenopathy: A novel meta-analysis.
Harling L; Jayakumar S; Ashrafian H; Bille A; Toufektzian L; Smith D
JTCVS Open; 2021 Mar; 5():121-130. PubMed ID: 36003173
[TBL] [Abstract][Full Text] [Related]
18. Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.
Hui Z; Men Y; Hu C; Kang J; Sun X; Bi N; Zhou Z; Liang J; Lv J; Feng Q; Xiao Z; Chen D; Wang Y; Li J; Wang J; Gao S; Wang L; He J
JAMA Oncol; 2021 Aug; 7(8):1178-1185. PubMed ID: 34165501
[TBL] [Abstract][Full Text] [Related]
19. The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC).
Muley T; Rolny V; He Y; Wehnl B; Escherich A; Warth A; Stolp C; Schneider MA; Dienemann H; Meister M; Herth FJ; Dayyani F
Lung Cancer; 2018 Jun; 120():46-53. PubMed ID: 29748014
[TBL] [Abstract][Full Text] [Related]
20. Postneoadjuvant adjuvant chemotherapy in resected N1 non-small cell lung cancer with residual nodal disease.
Smithy JW; Rosen JE; Gao SJ; Kim AW
J Surg Oncol; 2017 Dec; 116(8):1193-1196. PubMed ID: 29314062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
